Skip to main content

VICC treats first patient in Tennessee with novel cellular immunotherapy

Submitted by vicc_migrate on
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

HDAC3 role in B-cell development

Submitted by vicc_migrate on
 

Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.

Precision medicine already changing cancer treatment strategies

Submitted by vicc_migrate on
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]

Study explores how some breast cancers resist treatment

Submitted by vicc_migrate on
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]

Study details rare heart risk of certain cancer therapies

Submitted by vicc_migrate on
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]

Breast cancer program lands new research grants

Submitted by vicc_migrate on
Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]

Drivers of breast cancer metastasis

Submitted by vicc_migrate on
Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.
Subscribe to Research